文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

国际严重急性呼吸与新兴感染(ISARIC)COVID-19研究中重症COVID-19患者的呼吸支持:一项前瞻性、多国、观察性研究

Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study.
PubMed 文献 · Crit Care · 2022-09-13
一句话结论重症COVID-19患者中HFNC/NIV失败率15.5%,高白细胞计数、呼吸急促和LMIC治疗是失败的危险因素,失败与28天死亡率升高相关。

该研究为嵌入ISARIC-WHO COVID-19临床特征方案的多国、多中心、前瞻性队列研究,纳入入院24小时内接受HFNC、NIV或IMV的实验室确诊SARS-CoV-2感染住院患者66,565例。高收入国家(HIC)患者更多接受HFNC(48.0%),而低中收入国家(LMIC)患者多数接受IMV(59.1%)。无创呼吸支持失败率15.5%,失败与入院高白细胞计数(OR 5.86)、LMIC治疗(OR 2.04)和呼吸急促(OR 1.16)相关,失败者28天病死率更高(OR 1.27)。

要点

  • 66,565例重症COVID-19患者中,HIC入院24小时内HFNC使用率48.0%、NIV 38.6%、IMV 13.4%;LMIC HFNC仅16.1%、IMV达59.1%。
  • 无创呼吸支持(HFNC或NIV)失败率15.5%,其中71.2%来自HIC,28.8%来自LMIC。
  • 无创呼吸支持失败(进展为IMV)的危险因素:入院高白细胞计数OR 5.86(95%CI 4.83-7.10)、LMIC治疗OR 2.04(95%CI 1.97-2.11)、入院呼吸急促OR 1.16(95%CI 1.14-1.18)。
  • HFNC/NIV失败患者28天病死率更高,OR 1.27(95%CI 1.25-1.30)。

适用人群与场景

  • 实验室确诊SARS-CoV-2感染并需要住院治疗的患者。
  • 入院24小时内接受HFNC、NIV或IMV的患者纳入研究。
  • 研究覆盖高收入国家(HIC)和低中收入国家(LMIC)的多国、多中心前瞻性队列。

研究设计与关键结果

  • 研究类型:多国、多中心、前瞻性队列研究,嵌入ISARIC-WHO COVID-19临床特征方案;共纳入66,565例患者,82.6%在HIC治疗,40.6%在第一波疫情期间入院。
  • 入院24小时内呼吸支持分布:HIC患者HFNC 48.0%、NIV 38.6%、IMV 13.4%;LMIC患者HFNC 16.1%、IMV 59.1%。
  • 无创呼吸支持(HFNC或NIV)失败率15.5%,其中HIC占71.2%,LMIC占28.8%。
  • 无创通气失败(定义为进展为IMV)的相关变量:入院高白细胞计数OR 5.86(95%CI 4.83-7.10),LMIC治疗OR 2.04(95%CI 1.97-2.11),入院呼吸急促OR 1.16(95%CI 1.14-1.18)。
  • HFNC/NIV失败患者28天病死率更高,OR 1.27(95%CI 1.25-1.30)。

证据类型、等级与局限

  • 证据类型:前瞻性、多国、多中心观察性队列研究(ISARIC-WHO COVID-19临床特征方案)。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 在资源允许的HIC,HFNC是重症COVID-19最常用的高级呼吸支持方式;在LMIC,IMV使用更普遍。
  • 对入院时白细胞计数高或呼吸急促的重症COVID-19患者,应警惕HFNC/NIV失败风险,失败与28天病死率升高相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Up to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs).

METHODS: This is a multinational, multicentre, prospective cohort study embedded in the ISARIC-WHO COVID-19 Clinical Characterisation Protocol. Patients with laboratory-confirmed SARS-CoV-2 infection who required hospital admission were recruited prospectively. Patients treated with HFNC, NIV, or IMV within the first 24 h of hospital admission were included in this study. Descriptive statistics, random forest, and logistic regression analyses were used to describe clinical characteristics and compare clinical outcomes among patients treated with the different types of advanced respiratory support.

RESULTS: A total of 66,565 patients were included in this study. Overall, 82.6% of patients were treated in HIC, and 40.6% were admitted to the hospital during the first pandemic wave. During the first 24 h after hospital admission, patients in HICs were more frequently treated with HFNC (48.0%), followed by NIV (38.6%) and IMV (13.4%). In contrast, patients admitted in lower- and middle-income countries (LMICs) were less frequently treated with HFNC (16.1%) and the majority received IMV (59.1%). The failure rate of non-invasive respiratory support (i.e. HFNC or NIV) was 15.5%, of which 71.2% were from HIC and 28.8% from LMIC. The variables most strongly associated with non-invasive ventilation failure, defined as progression to IMV, were high leukocyte counts at hospital admission (OR [95%CI]; 5.86 [4.83-7.10]), treatment in an LMIC (OR [95%CI]; 2.04 [1.97-2.11]), and tachypnoea at hospital admission (OR [95%CI]; 1.16 [1.14-1.18]). Patients who failed HFNC/NIV had a higher 28-day fatality ratio (OR [95%CI]; 1.27 [1.25-1.30]).

CONCLUSIONS: In the present international cohort, the most frequently used advanced respiratory support was the HFNC. However, IMV was used more often in LMIC. Higher leucocyte count, tachypnoea, and treatment in LMIC were risk factors for HFNC/NIV failure. HFNC/NIV failure was related to worse clinical outcomes, such as 28-day mortality. Trial registration This is a prospective observational study; therefore, no health care interventions were applied to participants, and trial registration is not applicable.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Reyes LF, Murthy S, Garcia-Gallo E, et al. Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study. Crit Care. 2022. PMID: 36100904. doi:10.1186/s13054-022-04155-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。